Abstract | INTRODUCTION: METHODS: Post-menopausal women with advanced NSCLC received gefitinib 250 mg po daily and fulvestrant 250 mg IM monthly. RESULTS: Twenty-two patients were enrolled. Eight patients had adenocarcinoma, six NSCLC-NOS, four squamous cell, and four BAC. Seven patients were never-smokers. Eight patients received > or =2 lines of prior chemotherapy, six received one prior chemotherapy, and eight were treatment-naïve. One patient experienced grade 4 dyspnea possibly related to treatment; all other grade 3/4 toxicities were unrelated to treatment. Twenty patients were evaluable for response: three partial responses (PRs) were confirmed (response rate of 15%, 95% CI: 5-36%). The median progression-free survival (PFS), overall survival (OS), and estimated 1-year OS were 12 weeks (3-112 weeks), 38.5 weeks (7-135 weeks), and 41% (95% CI: 20-62%), respectively. Survival outcomes did not differ by prior lines of therapy. A subset analysis revealed that OS in the eight patients whose tumors exhibited at least 60% ERbeta nuclear IHC staining measured 65.5 weeks, while that of the five patients with ERbeta staining of less than 60% was 21 weeks. One patient with bronchioalveolar carcinoma (BAC) and a PR had an EGFR L858R mutation in exon 21. There was no correlation between ERbeta IHC expression and histology or smoking history. CONCLUSIONS:
|
Authors | Anne M Traynor, Joan H Schiller, Laura P Stabile, Jill M Kolesar, Jens C Eickhoff, Sanja Dacic, Tien Hoang, Sarita Dubey, Sarah M Marcotte, Jill M Siegfried |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 64
Issue 1
Pg. 51-9
(Apr 2009)
ISSN: 0169-5002 [Print] Ireland |
PMID | 18701186
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Quinazolines
- Fulvestrant
- Estradiol
- Gefitinib
|
Topics |
- Adenocarcinoma
(drug therapy, secondary)
- Adenocarcinoma, Bronchiolo-Alveolar
(drug therapy, secondary)
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, secondary)
- Estradiol
(administration & dosage, analogs & derivatives)
- Female
- Fulvestrant
- Gefitinib
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Pilot Projects
- Postmenopause
- Prognosis
- Quinazolines
(administration & dosage)
- Safety
- Survival Rate
- Treatment Outcome
|